Emerging studies suggest Retatru tide , a dual agonist targeting both GLP-1 and GIP , appears to offer a promising step forward for obesity treatment. Initial human investigations have indicated substantial reductions in visceral fat , possibly outperforming current body composition treatments. Nevertheless , further evaluation is needed to thoroug